Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stanford J, Stewart"'
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Dennis J. Slamon, Mansoor N. Saleh, Stanford J. Stewart, Joanne E. Mortimer, Andrew Arnold, Debasish Tripathy, Melody A. Cobleigh, M. Murphy
Publikováno v:
Journal of Clinical Oncology. 22:1063-1070
Purpose In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer. We conducted an exte
Autor:
Stanford J. Stewart, Michael Burchmore, Steven Shak, M. Murphy, William Novotny, Dennis J. Slamon, Louis Fehrenbacher, John Gutheil, Lyndsay Harris, Debasish Tripathy, Melody A. Cobleigh, Charles L. Vogel
Publikováno v:
European Journal of Cancer. 37:25-29
Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin(trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer
Autor:
Deborah L. Keefe, Clifford A. Hudis, Stanford J. Stewart, Andrew D. Seidman, Maureen E. Murphy, Mark Ashby, Mary Kathryn Pierri, Virginia E. Paton, Steven Shak
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(5)
PURPOSE: This study sought to estimate cardiac dysfunction (CD) risk for patients receiving trastuzumab; to characterize observed CD by severity, treatment, and clinical outcome; to assess effects of baseline clinical risk factors on CD; and to asses
Autor:
John K. Erban, Kathy D. Miller, Mark D. Pegram, Denise A. Yardley, Elizabeth Tan-Chiu, Seila Liv, Stanford J. Stewart, Hope S. Rugo
Publikováno v:
Journal of Clinical Oncology. 32:TPS671-TPS671
TPS671^ Background: Response to trastuzumab (T)-based chemoimmunotherapy in metastatic breast cancer segregates according to expression of the Fcg receptor, CD16A, allotypes with patients homozygou...
Autor:
Howard A. Burris, Todd M. Bauer, Giuseppe Giaccone, Jan Baughman, Seock-Ah Im, Hua Li, Stanford J. Stewart, Jane B. Trepel, David A Carlin, Jeffrey L. Nordstrom, Yung-Jue Bang
Publikováno v:
Journal of Clinical Oncology. 31:3004-3004
3004 Background: The anti-HER2 MAb, trastuzumab (H), has proven effective for HER2+ breast cancer (BC) and gastroesophageal cancer (GEC). H’s mechanism of action is incompletely understood, but evidence indicates ADCC is important. MGAH22 is an Fc-
Autor:
Wenjun Zhang, Paul A. Moore, Sergey Gorlatov, Yinhua Yang, Valentina Ciccarone, Tengfei Zhang, Jeffrey L. Nordstrom, Hua Li, Ezio Bonvini, Ling Huang, Jeffrey B. Stavenhagen, Syd Johnson, Stanford J Stewart, Scott Koenig, Steve Burke
Publikováno v:
Breast Cancer Research : BCR
Introduction Response to trastuzumab in metastatic breast cancer correlates with expression of the high binding variant (158V) of the activating Fcγ receptor IIIA (CD16A). We engineered MGAH22, a chimeric anti-HER2 monoclonal antibody with specifici